Lyell Immunopharma, Inc. (LYEL)

9.31 -0.09 (-0.96%) At close: 1:00PM EST

Lyell Immunopharma, Inc.

400 East Jamie Court
Suite 301
South San Francisco, CA 94080
United States
650 695 0677
http://www.lyell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 188

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard D. Klausner M.D.	Exec. Chairman	1.43M	N/A	1952
Ms. Elizabeth Homans	CEO & Director	1.14M	N/A	1966
Ms. Heather D. Turner	Chief Gen. Counsel & Sec.	917.08k	N/A	1973
Mr. Stephen J. Hill	Chief Operating Officer	722.58k	N/A	1970
Mr. Charles W. Newton	Chief Financial Officer	N/A	N/A	1971
Nellie Dillery	Director of Accounting	N/A	N/A	N/A
Mr. Richard Goold Ph.D.	Chief Information Officer	N/A	N/A	1960
Ms. Lisa Ryan	Chief People Officer	N/A	N/A	1967
Dr. Nicholas Restifo M.D.	Exec. VP of Research	N/A	N/A	1961
Ms. Elaine Cheung	Sr. VP of Corp. Strategy & Bus. Devel.	N/A	N/A	N/A

Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate governance

Lyell Immunopharma, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.